Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $12.00 price objective on the stock.

Several other research analysts have also recently weighed in on the company. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Rodman & Renshaw began coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective for the company. Maxim Group assumed coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective for the company. Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $9.50.

Quince Therapeutics Stock Up 3.7 %

QNCX stock opened at $1.95 on Thursday. The business’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $1.10. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The firm has a market capitalization of $85.80 million, a PE ratio of -1.57 and a beta of 0.74. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC increased its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after acquiring an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the Securities and Exchange Commission. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.